TOPOIIα and HER-2/neu overexpression/amplification in Barrett’s oesophagus, dysplasia and adenocarcinoma

Elisa Rossi, Vincenzo Villanacci, Gabrio Bassotti, Francesco Donato, Andrea Festa, Gianpaolo Cengia, Salvatore Grisanti & Renzo Cestari
2nd Department of Pathology, University of Brescia – Spedali Civili, Brescia, Gastroenterology & Hepatology Section, Department of Clinical & Experimental Medicine, University of Perugia, Perugia, Institute of Hygiene, Epidemiology and Public Health, Brescia University, Digestive Endoscopy, Department of General Surgery, University of Brescia – Spedali Civili, and Department of Medical Oncology, Spedali Civili, Brescia, Italy

Date of submission 28 March 2009
Accepted for publication 6 October 2009

Rossi E, Villanacci V, Bassotti G, Donato F, Festa A, Cengia G, Grisanti S & Cestari R (2010) Histopathology 57, 81–89

TOPOIIα and HER-2/neu overexpression/amplification in Barrett’s oesophagus, dysplasia and adenocarcinoma

Aims: Topoisomerase IIα (TOPOIIα) and HER-2/neu are chromosome 17q genes coamplified in various cancers; no data exist for Barrett’s oesophagus (BO) and BO adenocarcinoma (ADC). The aim was to investigate gene amplification and protein overexpression of TopoIIα and Her-2/neu in non-dysplastic BO, dysplastic BO, Barrett ADC, and chromosome 17 aneusomy.

Methods and results: Forty-four patients [18 BO, 13 BO with dysplasia (five low-grade dysplasia, eight high-grade dysplasia) and 13 ADC in BO] were evaluated by immunohistochemistry and fluorescence in situ hybridization (FISH). Genes (HER-2/neu and TOPOIIα) and chromosome 17 were evaluated by FISH. Patients with BO, dysplasia and ADC were compared. A significant association was found between TOPOIIα protein overexpression and TopoIIα gene amplification, chromosome 17 aneusomy, HER-2/neu gene amplification and HER-2 protein overexpression as well as between HER-2 protein and HER-2/neu gene, TopoIIα gene and aneusomy for chromosome 17, and between the genes TOPOIIα and HER-2/neu. Gene amplification (HER-2/neu, TOPOIIα), protein overexpression (HER-2/TOPOIIα), and chromosome 17 aneusomy were associated with dysplasia or ADC. Most BO patients showed no amplification/overexpression/aneusomy for the above genes, proteins and chromosome, with no differences between dysplasia and ADC.

Conclusions: HER-2/neu and TOPOIIα amplification/overexpression might discriminate between BO and dysplasia/ADC. Chromosome 17 aneusomy is associated with dysplasia or ADC in BO.

Keywords: adenocarcinoma, Barrett’s oesophagus, Her-2, TopoIIα

Introduction
HER-2/neu and topoisomerase IIα (TOPOIIα) genes are both located on chromosome 17q, and they can be co-amplified in cancer. Amplification of both genes has been reported in breast, prostatic, gastric, colorectal and pancreatic carcinomas. HER-2/neu oncogene encodes for the human epidermal growth factor receptor 2 (HER2/Neu), which is a transmembrane tyrosine kinase that is involved in cell proliferation, survival and migration. HER-2/neu gene amplification is a frequent event in various cancers, particularly breast, gastric and colorectal carcinomas, and it is associated with tumor progression, poor prognosis and resistance to chemotherapy.

Abbreviations: ADC, adenocarcinoma; BO, Barrett’s oesophagus; CEP17, chromosome enumeration probe 17; FDA, Food and Drug Administration; FISH, fluorescence in situ hybridization; H&E, haematoxylin and eosin; HGD, high-grade dysplasia; HPF, high-power field; LGD, low-grade dysplasia; SG, Spectrum Green; SO, Spectrum Orange; TOPOIIα, topoisomerase IIα.
factor receptor 2 and it is a well-known marker of poor prognosis in a variety of tumours.\textsuperscript{6,7}

There are two isoforms of mammalian topoisomerase II, \(\alpha\) and \(\beta\). DNA topoisomerase II catalyses a transient double-strand DNA break, which allows the passage of another DNA duplex through the break before the strands are resealed. TOPII\(\alpha\) represents the target enzyme for specific anticancer drugs, such as anthracyclines, commonly used for a variety of both haematological and solid neoplasms, including leukaemias, lymphomas and breast cancer. \textit{In vitro} studies have shown a correlation between the expression level of TOPII\(\alpha\) in cancer cells and the sensitivity of those cells to topoisomerase inhibitors.\textsuperscript{8,9}

Some authors have suggested a concordance of HER-2 and TOPII\(\alpha\) gene amplification in breast cancer,\textsuperscript{3} while others have demonstrated that TOPII\(\alpha\) amplification, identified by fluorescence \textit{in situ} hybridization (FISH), may occur with or without HER-2 duplication and is often associated with TOPII\(\alpha\) expression evaluated by immunohistochemistry.\textsuperscript{1}

In addition to the fact that amplification of HER-2 has become a valid biomarker to identify patients with breast cancer who respond to HER-2 protein targeting therapy, several recent clinical trials have found that HER-2-overexpressing breast cancers,\textsuperscript{10} with or without HER-2 amplification,\textsuperscript{11} are often responsive to anthracycline-based therapies. In fact, it has been proposed that HER-2 amplification in these tumours may be a marker of TOPII\(\alpha\) amplification.\textsuperscript{12}

Recent studies have confirmed that patients with breast cancer with TOPII\(\alpha\) gene amplification are more sensitive to TOPII\(\alpha\)-based therapy.\textsuperscript{13} However, it remains controversial whether gene amplification results in overexpression of the TOPII\(\alpha\) protein.\textsuperscript{9,14,15}

Adenocarcinoma (ADC) of the oesophagus is currently the cancer with the fastest increasing incidence in the USA, and has replaced squamous cell carcinoma as the most common oesophageal malignancy.\textsuperscript{16,17} In fact, an increase in relative and absolute numbers of ADCs of the lower third of the oesophagus has been observed in many Western countries. The most likely explanation for this finding seems to be the increasing prevalence of Barrett’s oesophagus (BO) as a consequence of gastro-oesophageal reflux, which is becoming more common with increasing levels of obesity.

The present study was undertaken to investigate: (i) the role of amplification/overexpression of TOPII\(\alpha\) and HER-2/neu genes and proteins, (ii) the association between TOPII\(\alpha\) amplification/overexpression, HER-2/neu amplification/overexpression and chromosome 17 aneusomy, and (iii) the association between TOPII\(\alpha\) and HER-2/neu amplification/overexpression and chromosome 17 aneusomy and the presence of BO, low-grade (LGD) or high-grade dysplasia (HGD) and ADC.

**Patients and methods**

**PATIENT SELECTION, CLINICAL AND ENDOSCOPIC EVALUATION**

The clinical records and histological specimens of 44 patients (six women and 38 men, age range 39–89 years) with a confirmed diagnosis of BO were analysed retrospectively. All patients underwent surveillance endoscopy at regular intervals or when clinically indicated at the Digestive Endoscopy Unit of the University of Brescia. Inclusion criteria were: a confirmed histological diagnosis of BO, oesophageal dysplasia (LGD and HGD) and ADC. Overall, specimens were obtained in 32 patients from biopsies and in 12 patients from mucosectomies.

**PATHOLOGICAL EVALUATION**

Immediately after sampling, the specimens were fixed in 10% neutral-buffered formalin for 24 h, routinely processed in paraffin and stained with haematoxylin and eosin (H&E) and Alcian-periodic acid–Schiff for routine histological examination. H&E-stained slides from the resection specimens were evaluated for identification of the steps in cancer progression. ADC and precursor lesions were diagnosed according to the World Health Organization classification,\textsuperscript{18} as previously reported.\textsuperscript{19,20} We selected those slides with obvious areas showing BO (100% showed areas with BO not associated with dysplasia), LGD (in >90% of the areas), HGD (in >90%) and ADC (in >90%). The cases of dysplasia were not associated with an invasive carcinoma.

Serial 3-\(\mu\)m sections were cut for FISH and immunohistochemistry, and the first and last sections of each series were stained with H&E. Corresponding areas on sequential sections were thus investigated by the two methods and for both Topo II\(\alpha\) and Her-2/neu.

HER-2 and TOPII\(\alpha\) status was studied by immunohistochemistry and FISH on paraffin-embedded tissue. Numerical alterations of chromosome 17 [chromosome enumeration probe 17 (CEP17)] were also evaluated by FISH.

**Immunohistochemistry**

HER-2 receptor status was studied using the HercepTest kit (DAKO\textsuperscript{TM}, Carpinteria, CA, USA).
According to the recommendations of the manufacturer, tissue sections mounted on slides and stored at room temperature (25°C) were stained within 4–6 weeks from sectioning, in order to preserve the antigenicity, then the samples were counterstained with Mayer’s haematoxylin. **HER-2** oncoprotein expression was assessed by two investigators (E.R., V.V.), following the scoring system recommended by the manufacturer’s instructions and the Food and Drug Administration (FDA) guidelines. According to the Hercep Test® criteria.\(^{21,22}\) Immunoreactivity was scored as follows: 3+, complete and intense membranous reactivity of >10% of tumour cells; 2+, complete but moderate reactivity of >10% of cells; 1+, weak and incomplete reactivity in >10% of cells; and 0, no membranous reactivity, or reactivity in <10% of cells.

To evaluate TOPOII\(\alpha\) protein expression, formalin-fixed, 3 µm thick paraffin-embedded tissues were cut, mounted on charged slides, and dried. For immunohistochemistry, slides were deparaffinized and rehydrated in graded solutions of ethanol and distilled water. Endogenous peroxidase was blocked by incubation with Peroxidase Block and Protein Block (NovoLink Polymer Detection System; Novocastra Laboratories, Newcastle, UK) at room temperature, both for 5 min. The immunohistochemical method involved sequential application of primary antibody to TOPOII\(\alpha\) (H-231, a rabbit polyclonal antibody raised against amino acids 1301–1531 of TOPOII\(\alpha\) of human origin; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) diluted 1:50 for 45 min, then post primary block (NovoLink Polymer Detection System; Novocastra Laboratories) was applied at room temperature for 15 min and a NovoLink Polymer (NovoLink Polymer Detection System; Novocastra Laboratories) for another 15 min. The immunoprecipitate was visualized by treatment with 3’3-diaminobenzidine chromogen (NovoLink Polymer Detection System; Novocastra Laboratories) for 5 min and counterstained by haematoxylin (Dako). Immunoreactivity was considered positive for TOPOII\(\alpha\) when at least 10% of dysplastic/neoplastic cells were stained. We applied the same criteria proposed for the quantification of p53 in endometrial and breast carcinomas.\(^{23,24}\) All samples were scored quantitatively and qualitatively at ×40 high-power fields (HPF) in every section (Nikon Eclipse E400, Tokyo, Japan) (Area of high-power field = 0.146 mm\(^2\)). TOPOII\(\alpha\) was considered positive when it could be recognized as a nuclear brown stain by immunohistochemistry.

**FISH**

A FDA approved kit for HER-2 evaluation (PathVysion HER-2 DNA Probe Kit; Vysis Inc., Downers Grove, IL, USA) was used, according to the manufacturer’s recommendations. The kit consists of directly labelled fluorescent DNA probes specific for the **Her-2/neu** gene locus (17q11.2-q12), labelled by Spectrum Orange (SO) and a DNA probe specific for the \(\alpha\) satellite DNA sequence at the centromeric region of chromosome 17 (17p11.1-q11.1), labelled by Spectrum Green (SG).

TOPOII\(\alpha\) gene was labelled by a locus-specific identifier probe for D17Z1 mixed with a probe specific for the centromeric region of chromosome 17 (17p11.1-q11.1) (LSI TOPO2A SO/CEP17 SG; Vysis Inc.). We applied the same protocol and scoring for both HER-2 and TOPOII\(\alpha\).

Counterstaining of nuclei was performed using 4,6-diamidino-2-phenylindole. A special amplification pattern as **Her-2/neu** ‘signal clusters’, usually with >10 confluent signals, was observed, as previously described.\(^{25,26}\) Although gene amplification as ‘homo- geneously stained regions’ was clearly evident, this pattern did not allow precise signal enumeration. Thus, the whole area of each neoplastic lesion present in the tissue section was independently evaluated by two investigators (E.R., V.V.) with fluorescence microscopy (Nikon Optiphot-2, Florence, Italy) equipped with selective filters for the fluorochromes used, in HPF (magnification 600×). FISH images were captured and elaborated using Genikon software (Nikon Instruments S.p.A, Florence, Italy). The **Her-2/neu** gene locus was classified as amplified if there were more than twice the number of red (SO labelling) **Her-2/neu** signals than green (SG labelling) centromere 17 signals (ratio >2:1) per cell nucleus. The presence of more than two nuclear red signals accompanied by the same number of nuclear green signals was considered to be indicative of aneusomy (in this case polysomy) of chromosome 17 (ratio 1:1). Following these criteria\(^{21,27}\) the cell population of each HPF was classified as displaying disomy, polysomy or an amplification of the **Her-2/neu** gene.

For TOPOII\(\alpha\) and **HER-2** genes, control slides for FISH were bought from the same probe manufacturers (Vysis, FDA approved), while for immunohistochemical analysis for HER-2 protein control slides were provided by the kit used (Dako, FDA approved). For TOPOII\(\alpha\) immunohistochemical analysis (which is the only method not FDA approved) we used as control a slide of breast carcinoma previously shown to be positive with immunohistochemistry and also confirmed positive by FISH.

**STATISTICAL ANALYSIS**

The associations between TOPOII\(\alpha\) gene amplification/TOPOII\(\alpha\) protein overexpression and **HER-2/neu**...
Table 1. Characteristics of the patients and results of the gene marker investigation

| Case | Age | Sex | Diagnosis | IHC HER2 | IHC TOPOII (%) | FISH HER2/neu | FISH TOPOII | FISH CEP17 |
|------|-----|-----|-----------|---------|----------------|---------------|-------------|------------|
| 1    | 47  | M   | BO        | 1       | 5              | NA            | NA          | Disomy     |
| 2    | 64  | M   | BO        | 1       | 3              | NA            | NA          | Disomy     |
| 3    | 39  | M   | BO        | 0       | 1              | NA            | NA          | Disomy     |
| 4    | 78  | M   | BO        | 0       | 6              | NA            | NA          | Disomy     |
| 5    | 56  | M   | BO        | 1       | 12.7           | NA            | NA          | Disomy     |
| 6    | 33  | M   | BO        | 0       | 23             | NA            | NA          | Disomy     |
| 7    | 68  | M   | BO        | 1       | 25.3           | NA            | NA          | Disomy     |
| 8    | 61  | F   | BO        | 1       | 33             | NA            | NA          | Disomy     |
| 9    | 66  | M   | BO        | 0       | 3              | NA            | NA          | Disomy     |
| 10   | 69  | F   | BO        | 1       | 55.5           | NA            | NA          | Disomy     |
| 11   | 84  | M   | BO        | 0       | 33             | NA            | NA          | Disomy     |
| 12   | 74  | M   | BO        | 1       | 26.1           | NA            | NA          | Disomy     |
| 13   | 64  | M   | BO        | 1       | 31.2           | NA            | NA          | Disomy     |
| 14   | 48  | M   | BO        | 2       | 40             | NA            | NA          | Disomy     |
| 15   | 82  | M   | BO        | 0       | 8              | NA            | NA          | Disomy     |
| 16   | 67  | M   | BO        | 1       | 40.8           | NA            | NA          | Disomy     |
| 17   | 52  | M   | BO        | 0       | 14.44          | NA            | NA          | Disomy     |
| 18   | 75  | M   | BO        | 0       | 3.20           | NA            | NA          | Disomy     |
| 19   | 72  | F   | LGD       | 0       | 35             | NA            | NA          | Disomy     |
| 20   | 56  | M   | LGD       | 0       | 13             | NA            | NA          | Disomy     |
| 21   | 74  | F   | LGD       | 3       | 96             | A             | A           | Disomy     |
| 22   | 76  | M   | LGD       | 3       | 37             | A             | NA          | Aneusomy   |
| 23   | 77  | M   | LGD       | 2       | 50.2           | NA            | NA          | Disomy     |
| 24   | 59  | M   | HGD       | 1       | 58             | NA            | NA          | Aneusomy   |
| 25   | 89  | M   | HGD       | 0       | 38             | NA            | NA          | Disomy     |
| 26   | 76  | M   | HGD       | 3       | 60             | A             | A           | Aneusomy   |
| 27   | 48  | M   | HGD       | 1       | 44.5           | NA            | NA          | Disomy     |
| 28   | 85  | M   | HGD       | 3       | 90             | A             | A           | Disomy     |
| 29   | 53  | M   | HGD       | 3       | 87             | A             | A           | Aneusomy   |
| 30   | 82  | M   | HGD       | 3       | 100            | A             | A           | Disomy     |
| 31   | 51  | M   | HGD       | 3       | 37             | NA            | NA          | Disomy     |
gene amplification/HER-2 protein overexpression, chromosome 17 aneusomy, and the presence of BO, dysplasia (LGD or HGD) and ADC were evaluated by the usual methods for comparison of proportions. Histology was categorized at three levels: BO, oesophageal dysplasia (which includes LGD and HGD) and ADC. Immunohistochemistry for TopoIIα was categorized at four levels according to quartiles of the percentage: 0–25.0; 25.1–50.0; 50.1–75.0; and 75.1–100%. P-values <0.05 (two-tailed tests) were used to reject the null hypothesis. Immunohistochemistry for HER-2 protein was categorized at four levels based on the FDA's approved scoring system (0, 1, 2, 3); FISH for both TOPOIIα and HER-2/neu genes was considered positive when amplified and negative when not amplified, and FISH for chromosome 17 was considered positive or negative in the presence of chromosome aneusomy or disomy, respectively.

**Table 1.** (Continued)

| Case | Age | Sex | Diagnosis | IHC HER2 | IHC TOPOIIα (%) | FISH HER2/neu | FISH TOPOIIα | FISH CEP17 |
|------|----|-----|-----------|----------|----------------|--------------|--------------|------------|
| 32   | 69 | M   | ADC       | 1        | 53             | NA           | NA           | Aneusomy   |
| 33   | 75 | M   | ADC       | 3        | 100            | A            | A            | Disomy     |
| 34   | 89 | M   | ADC       | 1        | 42.3           | NA           | NA           | Aneusomy   |
| 35   | 67 | F   | ADC       | 1        | 84             | NA           | NA           | Aneusomy   |
| 36   | 83 | M   | ADC       | 2        | 49             | NA           | NA           | Aneusomy   |
| 37   | 78 | M   | ADC       | 2        | 43             | NA           | NA           | Aneusomy   |
| 38   | 80 | M   | ADC       | 1        | 49             | NA           | NA           | Disomy     |
| 39   | 71 | F   | ADC       | 3        | 80             | A            | A            | Aneusomy   |
| 40   | 58 | M   | ADC       | 3        | 87             | A            | A            | Aneusomy   |
| 41   | 76 | M   | ADC       | 1        | 65             | NA           | NA           | Disomy     |
| 42   | 68 | M   | ADC       | 3        | 65             | A            | A            | Disomy     |
| 43   | 77 | M   | ADC       | 2        | 97             | NA           | NA           | Aneusomy   |
| 44   | 73 | M   | ADC       | 3        | 75             | A            | A            | Disomy     |

M, male; F, female; BO, Barrett’s oesophagus; LGD, low-grade dysplasia; HGD, high-grade dysplasia; ADC, adenocarcinoma; IHC, immunohistochemistry; FISH, fluorescence in situ hybridization; A, amplified; NA, not amplified; CEP, chromosome enumeration probe.

IHC Her2: values from 0 to 3 were attributed according to Food and Drug Administration instructions.

**Results**

The characteristics of the 44 subjects included in the study and the results of the overexpression/amplification of the genes investigated are shown in Table 1. HER-2/neu gene copy number was higher because clusters were identified (>10 signals), whereas TOPOIIα copy number was lower because it was often possible to count the single spots. No deletions were seen in any of the 44 patients analysed. Almost perfect agreement (43/44, 98%) was found between FISH TOPOIIα and HER-2/neu gene amplification, with the single exception of subject 22 (P < 0.001).

A statistically significant association was found between immunohistochemical TOPOIIα protein overexpression and FISH TOPOIIα gene amplification (P < 0.001), FISH HER-2/neu gene amplification (P < 0.001), immunohistochemical HER-2 protein overexpression (P < 0.001) and FISH chromosome 17 aneusomy (P = 0.03). A strong association was also found between immunohistochemical HER-2 protein overexpression and FISH HER-2/neu gene amplification.

**Ethical Considerations**

Since this was a retrospective study, no individual patient identification was done and no study-driven clinical intervention was performed. Thus, a simplified Institutional Review Board approval for retrospective studies was obtained and no patient consent was necessary.
amplification ($P < 0.001$), FISH TOPOIIα gene amplification ($P < 0.001$) and FISH aneusomy for chromosome 17 ($P = 0.02$). No association was found between FISH chromosome 17 aneusomy and either FISH HER-2/neu or TOPOIIα gene amplification ($P > 0.1$ for both).

Table 2 shows the distribution of the three groups of subjects according to each gene/protein assessment and chromosome aneusomy/disomy. Gene amplification (FISH HER-2/neu and TOPOIIα), protein overexpression (HER-2, TOPOIIα) and chromosome 17 aneusomy were all associated with the presence of dysplasia or ADC with respect to BO ($P < 0.05$ for each comparison). Among subjects with BO, none showed HER-2/neu or TOPOIIα amplification or chromosome 17 aneusomy, and almost none had moderate to complete membranous immunoreactivity for HER-2 protein expression (immunohistochemistry) (score 2 or 3) or >50% TOPOIIα protein expression (immunohistochemistry) (quartiles 3–4). On the other hand, 30–61% of subjects with dysplasia or ADC showed gene amplification and protein overexpression for both HER-2/neu or TOPOIIα and chromosome 17 aneusomy. No significant differences in positivity were seen between dysplasia and ADC for any the

Table 2. Distribution of subjects according to gene amplification, protein expression and histology

| Chromosome 17 genes/proteins | BO No. (%) | Dysplasia (LGD-HGD) No. (%) | ADC No. (%) | All pathologies No. (%) | $P$-value* |
|--------------------------------|------------|----------------------------|------------|------------------------|-----------|
| Total subjects | 18 (100) | 13 (100) | 13 (100) | 44 (100) |  |
| HER-2 protein (IHC) | | | | | |
| 0 | 8 (44.4) | 3 (23.1) | 0 (–) | 11 (25.0) | 0.001 |
| 1 | 9 (50.0) | 3 (23.1) | 5 (38.5) | 17 (38.6) | |
| 2 | 1 (5.6) | 1 (7.7) | 3 (23.1) | 5 (11.4) | |
| 3 | 0 (–) | 6 (46.2) | 5 (38.5) | 11 (25) | |
| HER-2/neu gene (FISH) | | | | | |
| 0 (NA) | 18 (100) | 7 (53.8) | 8 (61.5) | 33 (75) | 0.002 |
| 1 (A) | 0 (–) | 6 (46) | 5 (38.4) | 11 (25) | |
| Chromosome 17 (FISH) | | | | | |
| 0 (Disomy) | 18 (100) | 9 (69.2) | 5 (38.5) | 32 (72.7) | 0.004 |
| 1 (Aneusomy) | 0 (–) | 4 (30.8) | 8 (61.5) | 12 (27.3) | |
| TopoIIα protein (IHC) | | | | | |
| 1 (1.0–25.0%) | 10 (55.5) | 1 (7.7) | 0 (–) | 11 (25) | 0.001 |
| 2 (25.1–50%) | 7 (38.9) | 5 (38.44) | 4 (30.8) | 16 (36.3) | |
| 3 (50.1–75%) | 1 (5.55) | 3 (23) | 4 (30.8) | 8 (18.1) | |
| 4 (75.1–100%) | 0 (–) | 4 (30.8) | 5 (38.44) | 9 (20.4) | |
| TopoIIα gene (FISH) | | | | | |
| 0 (NA) | 18 (100) | 8 (61.5) | 8 (61.55) | 34 (77.3) | 0.004 |
| 1 (A) | 0 (–) | 5 (38.4) | 5 (38.44) | 10 (22.7) | |

BO, Barrett’s oesophagus; LGD, low-grade dysplasia; HGD, high-grade dysplasia; ADC, adenocarcinoma; IHC, immunohistochemistry; FISH, fluorescence in situ hybridization; A, amplified; NA, not amplified.

*Exact tests for the comparison among proportions of patients with BO, dysplasia and ADC for each gene overexpression/amplification.
markers analysed. Representative images are shown in Figures 1 and 2.

With the single exception of case 22, all the cases of dysplasia and ADC showed co-amplification of TOPOIIα and HER-2/ neu genes (>50%). HER-2/ neu gene amplification was higher then TOPOIIα (Figure 1D) because of the clustering (>10 signals) (Figure 2B), as also reported in previous studies.3,4,28 No deletions were seen in any of the 44 patients analysed. There was no significant association between protein/gene overexpression/amplification and age or gender (data not shown).

Discussion

Topoisomerases are nuclear enzymes that regulate cellular processes such as replication and transcription; in addition, these enzymes represent a major molecular target for drugs of the anthracycline class or chemotherapeutic agents.9 Clinical and in vitro evidence supports the concept that in breast cancer the association between HER-2 amplification and response to anthracycline-based chemotherapy is not a direct effect of HER-2 overexpression but the result of co-amplification of the TOPOIIα gene.29 Some studies have shown that increased expression of TOPOIIα in BO is associated with HGD,30 as well as the fact that HER-2 is overexpressed in oesophageal ADC31 and this overexpression may predict early transition from dysplasia to ADC in BO.12 However, to the best of our knowledge the expression of TOPOIIα and HER-2 has not been previously investigated in BO patients.

In the present study we examined HER-2/ neu and TOPOIIα gene/protein by FISH and immunohistochemistry, respectively, and we also investigated chro-
mosome 17 status and histological features (BO, LGD, HGD and ADC).

In agreement with previous studies on breast carcinomas, we confirmed that TOPOIIα is rarely amplified in the absence of HER-2 amplification, that it is co-amplified with HER-2 in dysplasia (LGD and HGD) and ADC, and that the HER-2 gene copy number, because of clustering, was higher than the TOPOIIα copy number. Moreover, statistically significant associations were found between gene amplification and protein expression for both HER-2 and TOPOIIα, between HER-2 and TOPOIIα gene amplification and between HER-2 and TOPOIIα protein expression, confirming the results of previous studies regarding pancreatic and gastric cancers. Chromosome 17 aneusomy was found to be associated with TOPOIIα protein overexpression but not with each gene amplification. No deletions for TOPOIIα and/or HER-2/neu were seen in any of our patients, whereas monoallelic deletions were found in other pathological conditions, i.e. breast cancer.

We investigated the associations between the above-mentioned markers and pathological findings. We found HER-2/TOPOIIα gene amplification/protein overexpression and chromosome 17 aneusomy (polysomy) in a high proportion of patients with dysplasia (LGD and HGD) or ADC, but in almost none of the patients with BO, suggesting involvement of these factors in cancer development. It is well known that BO is associated with gastrointestinal acid reflux, and it has been suggested that acid reflux could introduce mutations in esophageal cells due to acid pH-induced DNA damage. However, acid reflux also causes inflammatory responses known to contribute to carcinogenesis.

Recent clinical studies have shown that TOPOIIα gene amplification is a more specific predictor than TOPOIIα expression assessed by immunohistochemistry and HER-2 gene amplification for clinical response to TOPOIIα inhibitors in breast cancer. For this reason, FISH testing for TOPOIIα status in addition to HER-2 evaluation may be useful in the characterization of Barrett’s pathology and progression to dysplasia. Furthermore, ascertaining TOPOIIα status might be useful to select patients for combination therapy: a trial could be designed to investigate whether patients with TOPOIIα amplification may be treated with HER-2 targeting drug together with a cytotoxic drug, such as TOPOIIα-inhibitor.

In conclusion, these findings suggest that the investigation of these markers might be useful in characterizing the evolution from BO to dysplasia and ADC. These potential markers might also contribute to deciding alternative therapeutic approaches, as suggested by some preliminary data.

Acknowledgements

The authors thank Professors Vanio Vannini and Cesare Danesino (University of Pavia), tutors of E.R. for the PhD in Pathology and Genetics, and Ms Anna Galletti, Ms Lucia Fontana and Ms Monica Brotto for providing technical support. E.R. is recipient of a grant from Ingenio Finlombarda S.p.a., Regione Lombardia, Italy.

References

1. Murphy AJ, Hughes CA, Barrett C et al. Low-level TOP2A amplification in prostate cancer is associated with HER2 duplication, androgen resistance, and decreased survival. Cancer Res. 2007; 15; 2893–2898.
2. Hansel DE, Ashfaq R, Rahman A et al. A subset of pancreatic adenocarcinomas demonstrates coamplification of topoisomerase IIalpha and HER2/neu: use of immunolabeling and multicolor FISH for potential patient screening and treatment. *Am. J. Clin. Pathol.* 2005; 123: 28–35.

3. Bouchalová K, Trojanec R, Kolar Z et al. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer. *Neoplasma* 2006; 53: 393–401.

4. Kanta SY, Yamane T, Dobushi Y, Mitsui F, Kono K, Ooi A. Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study. *Hum. Pathol.* 2006; 10: 1333–1343.

5. Al-Kuraya K, Novotny H, Bavi P et al. HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. *J. Clin. Pathol.* 2007; 60: 768–772.

6. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. *Stem Cells* 1998; 16: 413–428.

7. Brien TP, Odze RD, Sheehan CE, McKenna BJ, Ross JS. HER-2/neu gene amplification by FISH predicts poor survival in Barrett’s esophagus-associated adenocarcinoma. *Hum. Pathol.* 2000; 31: 35–39. Erratum in: *Hum. Pathol.* 2000; 31: 524.

8. Isaacs RJ, Davies SL, Wells NJ, Harris AL. Topoisomerases IIalpha and beta as therapy targets in breast cancer. *Anticancer Drugs* 1995; 6: 195–211.

9. Jarvinen TA, Tanner M, Rantanen V et al. Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. *Am. J. Pathol.* 2000; 156: 839–847.

10. Paik S, Bryant J, Tan-Chiu E et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. *J. Natl Cancer Inst.* 2000; 92: 1991–1998.

11. Thor AD, Berry DA, Budman DR et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. *J. Natl Cancer Inst.* 1998; 90: 1346–1360.

12. Lynch BJ, Guiney DG Jr, Holden JA. Human DNA topoisomerase IIalpha: a new marker of cell proliferation in invasive breast cancer. *Hum. Pathol.* 1997; 28: 1180–1188.

13. Di Leo A, Gancberg D, Larsimont D et al. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. *Clin. Cancer Res.* 2002; 8: 1107–1116.

14. Coon JS, Marcus E, Gupta-Burt S et al. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. *Clin. Cancer Res.* 2002; 8: 1061–1067.

15. Mueller RE, Parkes RK, Andrulis I, O’Malley FP. Amplification of the TOP2A gene does not predict high levels of topoisomerase IIalpha protein in human breast tumor samples. *Genes Chromosomes Cancer* 2004; 39: 288–297.

16. Paulson TG, Reid BJ. Focus on Barrett’s esophagus and esophageal adenocarcinoma. *Cancer Cell* 2004; 6: 11–16.

17. DeMeester SR. Adenocarcinoma of the esophagus and cardia: a review of the disease and its treatment. *Ann. Surg. Oncol.* 2006; 13: 12–30.

18. Hamilton SR, Aaltonen LA. *WHO pathology and genetics: tumors of digestive system*. Lyon: IARC Press, 2000.

19. Villanacci V, Rossi E, Zambelli C et al. COX-2, CDX2, and CDC2 immunohistochemical assessment for dysplasia–carcinoma progression in Barrett’s esophagus. *Dig. Liver Dis.* 2007; 39: 305–311.

20. Villanacci V, Bellone G, Battaglia E et al. Ski/SnoN expression in the sequence metaplasia–dysplasia–adenocarcinoma of Barrett’s esophagus. *Hum. Pathol.* 2008; 39: 403–409.

21. Ellis IO, Dowsett M, Bartlett J et al. Recommendations for HER2 testing in the UK. *J. Clin. Pathol.* 2000; 53: 890–892.

22. Dowsett M, Hanna WM, Koock M et al. Standardization of HER2 testing: results of an international proficiency-testing ring study. *Mod. Pathol.* 2007; 20: 584–591.

23. McCarthy NJ, Yang X, Linnola IR et al. Microvessel density, expression of estrogen receptor alpha, MB-1, p53, and c-erbB-2 in inflammatory breast cancer. *Clin. Cancer Res.* 2002; 8: 3857–3862.

24. Mazurek A, Pierzynski P, Kuc P et al. Evaluation of angiogenesis, p-53 tissue protein expression and serum VEGF in patients with endometrial cancer. *Neoplasma* 2004; 51: 193–197.

25. Ishikawa T, Kobayashi M, Mai M, Suzuki T, Ooi A. Amplification of the c-erbB2 (HER2/neu) gene in gastric cancer cells. Detection by fluorescence in situ hybridization. *Am. J. Pathol.* 1997; 151: 761–768.

26. Walch A, Bink K, Gais P et al. Evaluation of c-erbB2 overexpression and Her-2/neu gene copy number heterogeneity in Barrett’s adenocarcinoma. *Anal. Cell. Pathol.* 2000; 20: 25–32.

27. Ellis IO, Bartlett J, Dowsett M et al. Best practice no 176: updated recommendations for HER2 testing in the UK. *J. Clin. Pathol.* 2004; 57: 233–237.

28. Brüderlein S, van der Bosch K, Schlag P, Schwab M. Cytogenetics and DNA amplification in colorectal cancers. *Genes Chromosomes Cancer* 1990; 2: 63–70.

29. Hicks DG, Yoder BJ, Pettay J et al. The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study. *Hum. Pathol.* 2005; 36: 348–356.

30. Sabo E, Meitner PA, Tavares R et al. Expression analysis of Barrett’s esophagus-associated high-grade dysplasia in laser capture microdissected archival tissue. *Clin. Cancer Res.* 2008; 14: 6440–6448.

31. Rausser S, Weis R, Braselmann H et al. Significance of HER2 low-level copy gain in Barrett’s cancer: implications for fluorescence in situ hybridization testing in tissues. *Clin. Cancer Res.* 2007; 13: 5115–5123.

32. Rossi E, Grisanti S, Villanacci V et al. HER-2 overexpression/amplification in Barrett’s esophagus predicts early transition from dysplasia to adenocarcinoma: a clinico-pathologic study. *J. Cell Mol. Med.* 2009; 13: 3826–3833.

33. Wild CP, Hardie LJ, Reflux, Barrett’s oesophagus and adenocarcinoma: burning questions. *Nat. Rev. Cancer* 2003; 3: 676–684.

34. Schottenfeld D, Beebe-Dimmer J. Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. *CA Cancer J. Clin.* 2006; 56: 69–83.

35. Di Leo A, Isola J. Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: are we at the end of the beginning? *Clin. Breast Cancer* 2003; 4: 179–186.

36. Villanacci V, Rossi E, Grisanti S et al. Targeted therapy with trastuzumab in dysplasia and adenocarcinoma arising in Barrett’s esophagus: a translational approach. *Minerva Gastroenterol. Dietol.* 2008; 54: 347–353.